Salicylanilide carbamates: Promising antibacterial agents with high in vitro activity against methicillin-resistant Staphylococcus aureus (MRSA)
Language English Country Netherlands Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
26079401
DOI
10.1016/j.ejps.2015.06.009
PII: S0928-0987(15)00304-8
Knihovny.cz E-resources
- Keywords
- Alkylcarbamates, Antibacterial activity, MRSA, Salicylanilides, Structure–activity relationships, Time-kill assay,
- MeSH
- Anti-Bacterial Agents pharmacology MeSH
- Cell Line MeSH
- Humans MeSH
- Methicillin-Resistant Staphylococcus aureus drug effects MeSH
- Microbial Sensitivity Tests MeSH
- Salicylanilides pharmacology MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Anti-Bacterial Agents MeSH
- salicylanilide MeSH Browser
- Salicylanilides MeSH
A series of twenty-one salicylanilide N-alkylcarbamates was assessed for novel antibacterial characteristics against three clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA) and S. aureus ATCC 29213 as the reference and quality control strain. The minimum inhibitory concentration was determined by the broth dilution micro-method with subsequent subcultivation of aliquots to assess minimum bactericidal concentration. The bactericidal kinetics was established by time-kill assay. Ampicillin, ciprofloxacin and vancomycin were used as reference antibacterial drugs. All the tested compounds exhibited highly potent anti-MRSA activity (⩽ 0.008-4 μg/mL) comparable or up to 250× higher than that of vancomycin, the standard in the treatment of serious MRSA infections. 4-Chloro-2-(3,4-dichlorophenylcarbamoyl)phenyl butylcarbamate and 4-chloro-2-(3,4-dichlorophenylcarbamoyl)phenyl ethylcarbamate were the most active compounds. In most cases, compounds provided reliable bacteriostatic activity, except for 4-chloro-2-(4-chlorophenylcarbamoyl)phenyl decylcarbamate exhibiting bactericidal effect at 8h (for clinical isolate of MRSA 63718) and at 24h (for clinical isolates of MRSA SA 630 and MRSA SA 3202) at 4× MIC. Structure-activity relationships are discussed.
References provided by Crossref.org
Study of Biological Activities and ADMET-Related Properties of Salicylanilide-Based Peptidomimetics
Study of Biological Activities and ADMET-Related Properties of Novel Chlorinated N-arylcinnamamides
Biological Activities and ADMET-Related Properties of Novel Set of Cinnamanilides
Investigation of Anti-Inflammatory Potential of N-Arylcinnamamide Derivatives
Synthesis and Spectrum of Biological Activities of Novel N-arylcinnamamides
N-Alkoxyphenylhydroxynaphthalenecarboxamides and Their Antimycobacterial Activity